NCT06858410 2025-03-05Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaGuangdong Association of Clinical TrialsPhase 3 Not yet recruiting36 enrolled